2025 is set to change the industry. The new administration is poised to challenge many existing processes. The question is whether they will be based on data-driven analysis or ideologies and beliefs.
Our guests address this concern along with the existing challenges CEOs face, particularly manufacturing processes.
Additionally, they discuss weight loss drugs, focusing on GLP-1s, with medical precision.
 
Host
<a href="https://www.linkedin.com/in/lorielliskatz/" rel="ugc noopener noreferrer" target="_blank">⁠Lori Ellis⁠</a>, Head of Insights, BioSpace
 
Guests
<a href="https://www.linkedin.com/in/miguel-forte-4741761/overlay/about-this-profile/" rel="ugc noopener noreferrer" target="_blank">⁠Miguel Forte⁠</a>, President, International Society for Cell &amp; Gene Therapy; Board Member, ARM; CEO and Board Member, Kiji Therapeutics
<a href="https://www.linkedin.com/in/ali-pashazadeh-8490b841?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAAAi8RbkBmIGAFGWUlYgXxDt-LeSx7IlBQ8A" rel="ugc noopener noreferrer" target="_blank">⁠Ali Pashazadeh,⁠</a> Founder, Treehill Partners

Trials and Capital: Women’s Health and APAC's Healthcare Revolution

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.